Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl)acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide
作者:Maciej Dawidowski、Marek Król、Bartłomiej Szulczyk、Andrzej Chodkowski、Piotr Podsadni、Piotr Konopelski、Marcin Ufnal、Piotr Szuberski、Martyna Zofia Wróbel、Yihong Zhang、Aziza El Harchi、Jules C. Hancox、Dagmar Jarkovska、Eliska Mistrova、Jitka Sviglerova、Milan Štengl、Grzegorz M. Popowicz、Jadwiga Turło
DOI:10.1016/j.bioorg.2020.103717
日期:2020.5
their anticonvulsant activity in animal models of epilepsy. The compounds were broadly active in the 'classical' maximal electroshock seizure (MES) and subcutaneous Metrazol (scMET) tests as well as in the 6 Hz and kindling models of pharmacoresistant seizures. Furthermore, the compounds showed good therapeutic indices between anticonvulsant activity and motor impairment. Structure-activity relationship
合成了一系列的2-芳基-2-(吡啶-2-基)乙酰胺,并在癫痫动物模型中筛选了它们的抗惊厥活性。这些化合物在“经典”最大电击发作(MES)和皮下Metrazol(scMET)测试以及在6 Hz和点燃性药物耐受性发作模型中具有广泛的活性。此外,这些化合物在抗惊厥活性和运动障碍之间显示出良好的治疗指数。结构-活性关系(SAR)趋势清楚地表明,最高活性在于未取代的苯基衍生物或在苯环上具有邻位和间位取代基的化合物。2-芳基-2-(吡啶-2-基)乙酰胺是通过对心脏毒性的钠通道阻滞剂二吡酰胺(DISO)进行重新设计而获得的。我们的结果表明,在膜片钳实验中,这些化合物保留了母体化合物抑制电压门控钠电流的能力。但是,与DISO相比,系列1中的代表性化合物在一系列体外和体内实验中显示出较高的心脏安全性。